Congress will decide whether or not to start contempt proceedings against the CEO of Valeant next week

J.
Michael Pearson, Chairman of the board and Chief Executive
Officer of Valeant Pharmaceuticals International Inc., speaks
during their annual general meeting in Laval, Quebec May 20,
2014.REUTERS/Christinne
Muschi

On Wednesday, members of the Special Committee on Aging will
decide whether or not to initiate contempt proceedings against
the CEO of Valeant Pharmaceuticals, Michael Pearson.

The move comes after the committee last month issued a
Subpoena and Deposition Notice compelling J. Michael Pearson,
Chief Executive Officer of Valeant Pharmaceuticals International
to personally appear for a deposition on Friday.

Mr. Pearson did not appear at the deposition.

The Committee will meet to consider next steps with respect to
Mr. Pearson’s failure to appear.

Here's some of the text from the notice:

Business Meeting

Special Committee on Aging United States Senate 114th
Congress, 1st Session Hearing/Meeting Schedule